VTVT vs. DBVT, AVTE, YMAB, ACTU, ENGN, SCPH, CTMX, DRUG, CRGX, and IPHA
Should you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include DBV Technologies (DBVT), Aerovate Therapeutics (AVTE), Y-mAbs Therapeutics (YMAB), Actuate Therapeutics (ACTU), enGene (ENGN), scPharmaceuticals (SCPH), CytomX Therapeutics (CTMX), Bright Minds Biosciences (DRUG), CARGO Therapeutics (CRGX), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry.
vTv Therapeutics vs.
vTv Therapeutics (NASDAQ:VTVT) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.
17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 4.2% of vTv Therapeutics shares are owned by company insiders. Comparatively, 1.4% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
vTv Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -815.73%. DBV Technologies' return on equity of -106.07% beat vTv Therapeutics' return on equity.
In the previous week, vTv Therapeutics had 1 more articles in the media than DBV Technologies. MarketBeat recorded 3 mentions for vTv Therapeutics and 2 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.52 beat vTv Therapeutics' score of 0.95 indicating that DBV Technologies is being referred to more favorably in the news media.
vTv Therapeutics has higher earnings, but lower revenue than DBV Technologies. vTv Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.
DBV Technologies received 56 more outperform votes than vTv Therapeutics when rated by MarketBeat users. However, 57.12% of users gave vTv Therapeutics an outperform vote while only 54.17% of users gave DBV Technologies an outperform vote.
vTv Therapeutics currently has a consensus target price of $35.50, suggesting a potential upside of 109.87%. DBV Technologies has a consensus target price of $14.75, suggesting a potential upside of 63.89%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than DBV Technologies.
vTv Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500.
Summary
vTv Therapeutics beats DBV Technologies on 11 of the 18 factors compared between the two stocks.
Get vTv Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
vTv Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VTVT) was last updated on 6/11/2025 by MarketBeat.com Staff
